Wall Street Zen Upgrades Tilray Brands (NASDAQ:TLRY) to “Hold”

Tilray Brands (NASDAQ:TLRY) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other analysts have also recently commented on the stock. Roth Mkm lowered their target price on shares of Tilray Brands from $20.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. ATB Cormark Capital Markets upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 10th. Zacks Research raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. Canaccord Genuity Group began coverage on shares of Tilray Brands in a report on Tuesday, January 27th. They set a “hold” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $13.33.

Tilray Brands Stock Performance

Shares of Tilray Brands stock opened at $6.21 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.72 and a current ratio of 2.81. The company has a market capitalization of $723.53 million, a PE ratio of -0.28 and a beta of 1.96. The company has a 50-day simple moving average of $7.83 and a two-hundred day simple moving average of $10.54. Tilray Brands has a one year low of $3.51 and a one year high of $23.20.

Tilray Brands (NASDAQ:TLRY) last posted its earnings results on Thursday, January 8th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.12. Tilray Brands had a negative net margin of 251.69% and a negative return on equity of 6.35%. The company had revenue of $217.51 million during the quarter, compared to analysts’ expectations of $211.15 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. Research analysts expect that Tilray Brands will post -0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TLRY. AQR Capital Management LLC boosted its holdings in Tilray Brands by 1,839.7% in the first quarter. AQR Capital Management LLC now owns 607,054 shares of the company’s stock valued at $399,000 after purchasing an additional 575,757 shares during the last quarter. Swiss National Bank raised its stake in shares of Tilray Brands by 6.1% during the 2nd quarter. Swiss National Bank now owns 1,928,138 shares of the company’s stock valued at $799,000 after buying an additional 111,500 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Tilray Brands in the 2nd quarter valued at about $112,000. J.W. Cole Advisors Inc. lifted its holdings in shares of Tilray Brands by 203.2% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company’s stock valued at $30,000 after buying an additional 48,177 shares during the period. Finally, Cerity Partners LLC boosted its stake in shares of Tilray Brands by 98.5% in the second quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock worth $38,000 after buying an additional 45,929 shares during the last quarter. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Key Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray Medical announced its largest medical-cannabis portfolio expansion in Australia, reinforcing patient access and signaling commitment to a growth market — a revenue and patient-share catalyst for TLRY’s medical segment. Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia
• Positive Sentiment: Tilray Medical, CC Pharma and 14U Pharma formed a strategic alliance with “gesund leben” and Alliance Healthcare Deutschland to accelerate market expansion in Germany — a distribution and commercialization boost for EU sales. Tilray Medical, CC Pharma, and 14U Pharma Announce Strategic Alliance
• Positive Sentiment: CEO Irwin Simon told Just Drinks the company is focused on “putting stability in place” for BrewDog — signaling management attention on operational turnaround and margin stabilization in its beverage segment. “We need to put stability in place” – Tilray Brands CEO on what lies ahead for BrewDog
• Neutral Sentiment: Market write-ups note TLRY is slipping more than the broader market in recent sessions—useful short-term context but largely descriptive of current flow rather than new fundamental news. Tilray Brands, Inc. (TLRY) Dips More Than Broader Market: What You Should Know
• Negative Sentiment: Technical analysts warn TLRY has lost a key support level and suggest downside toward ~$5 is possible if selling continues — a short-term bearish signal that can amplify downside as stops trigger. Tilray stock price has just lost a key support: is a crash to $5 coming?

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.